Neurocrine Biosciences (NBIX) Capital Expenditures Growth (5y) (2015 - 2026)
Neurocrine Biosciences (NBIX) Capital Expenditures Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 69.52% |
| Dec 31, 2025 | -17.55% |
| Sep 30, 2025 | 180.13% |
| Jun 30, 2025 | -145.95% |
| Mar 31, 2025 | 67.98% |
| Dec 31, 2024 | 40.27% |
| Sep 30, 2024 | -17.37% |
| Jun 30, 2024 | -95.19% |
| Mar 31, 2024 | 79.56% |
| Dec 31, 2023 | -41.32% |
| Sep 30, 2023 | 15.12% |
| Jun 30, 2023 | -50.07% |
| Dec 31, 2022 | -51.15% |
| Sep 30, 2022 | 24.77% |
| Jun 30, 2022 | -6.88% |
| Mar 31, 2022 | 15.50% |
| Dec 31, 2021 | 34.28% |
| Sep 30, 2021 | 73.74% |
| Jun 30, 2021 | -1.31% |
| Mar 31, 2021 | -33.01% |